494847-54-0

Basic information

• Product Name: 5-[(3-tert-Butoxycarbonyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carbonyl)-amino]-isophthalic acid dibenzyl ester
• Synonyms: 5-[(3-tert-Butoxycarbonyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carbonyl)-amino]-isophthalic acid dibenzyl ester
• CAS NO: 494847-54-0
• Molecular Weight: 634.729
• Mol File: 494847-54-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-[(3-tert-Butoxycarbonyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carbonyl)-amino]-isophthalic acid dibenzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[(3-tert-Butoxycarbonyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carbonyl)-amino]-isophthalic acid dibenzyl ester(494847-54-0)
• EPA Substance Registry System: 5-[(3-tert-Butoxycarbonyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carbonyl)-amino]-isophthalic acid dibenzyl ester(494847-54-0)

Safety Data

• Hazardous Substances Data: 494847-54-0(Hazardous Substances Data)

Upstream product

• 188990-16-1 2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carboxylic acid hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 152699-63-3 5-Amino-isophthalic acid dibenzyl ester 
• 192133-86-1 N-(tert-butoxycarbonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-2-carboxylic acid 

Downstream Products

• 192133-94-1 5-{[3-(6-Carboxy-3H-benzoimidazole-5-carbonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carbonyl]-amino}-isophthalic acid dibenzyl ester 
• 192133-98-5 5-[[[[3,5-bis(benzyloxycarbonyl)phenyl]amino]carbonyl]-[2-(2,3,4,5-tetrahydro-1H-3-benzazepino)carbonyl]]-6-[[(1-adamantanemethyl)amino]carbonyl]benzimidasole 
• 192133-90-7 2-[[[3,5-bis(benzyloxycarbonyl)phenyl]amino]carbonyl]-2,3,4,5-tetrahydro-1H-3-benzazepine 

Relevant articles and documents

CCK2 receptor antagonists containing the conformationally constrained phenylalanine derivatives, including the new amino acid Xic

The conformationally constrained analogues of phenylalanine, tetrahydroisoquinoline-3-carboxylic acid (Tic), Sic, Hic and Nic, and the new amino acid Xic have been incorporated into a potent and highly selective cholecystokinin-2 (CCK2) receptor antagonist (2) in place of the phenylalanine residue, producing compounds 15a-e. High selectivities for CCK2 over CCK1 were observed for compounds 15a-e. The in vitro profile of the analogue containing the Nic residue (15d) was identical to that of compound 2, whereas the alternative conformational constraints resulted in a significant loss of affinity. The apparent advantage of Nic in the context of these CCK2 ligands was subsequently demonstrated to be statistically significant.